198 research outputs found
Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
Background: Despite standard treatment for epithelial ovarian cancer (EOC), that involves cytoreductive surgery
followed by platinum-based chemotherapy, and initial high response rates to these, up to 80 % of patients experience
relapses with a median progression-free survival of 12–18 months. There remains an urgent need for novel targeted
therapies to improve clinical outcomes in ovarian cancer. Of the many targeted therapies currently under evaluation,
the most promising strategies developed thus far are antiangiogenic agents and Poly(ADP-ribose) polymerase
(PARP) inhibitors. Particularly, PARP inhibitors are active in cells that have impaired repair of DNA by the homologous
recombination (HR) pathway. Cells with mutated breast related cancer antigens (BRCA) function have HR deficiency,
which is also present in a significant proportion of non-BRCA-mutated ovarian cancer (“BRCAness” ovarian cancer).
The prevalence of germline BRCA mutations in EOC has historically been estimated to be around 10–15 %. However,
recent reports suggest that this may be a gross underestimate, especially in women with high-grade serous ovarian
cancer (HGSOC).
Main body of the abstract: The emergence of the DNA repair pathway as a rational target in various cancers led
to the development of the PARP inhibitors. The concept of tumor-selective synthetic lethality heralded the beginning
of an eventful decade, culminating in the approval by regulatory authorities both in Europe as a maintenance
therapy and in the United States treatment for advanced recurrent disease of the first oral PARP inhibitor, olaparib, for
the treatment of BRCA-mutated ovarian cancer patients. Other PARP inhibitors are clearly effective in this disease and,
within the next years, the results of ongoing randomized trials will clarify their respective roles.
Conclusion: This review will discuss the different PARP inhibitors in development and the potential use of this
class of agents in the future. Moreover, combination strategies involving PARP inhibitors are likely to receive increasing
attention. The utility of PARP inhibitors combined with cytotoxic chemotherapy is of doubtful value, because of
enhanced toxicity of this combination; while, more promising strategies include the combination with antiangiogenic
agents, or with inhibitors of the P13K/AKT pathway and new generation of immunotherapy
Niraparib in ovarian cancer. results to date and clinical potential
Ovarian cancer is the first cause of death from gynaecological malignancy. Germline mutation in BRCA1 and 2, two genes involved in the mechanisms of reparation of DNA damage, are showed to be related with the incidence of breast and ovarian cancer, both sporadic and familiar. PARP is a family of enzymes involved in the base excision repair (BER) system. The introduction of inhibitors of PARP in patients with BRCA-mutated ovarian cancer is correlated with the concept of synthetic lethality. Among the PARP inhibitors introduced in clinical practice, niraparib showed interesting results in a phase III trial in the setting of maintenance treatment in ovarian cancer, after platinum-based chemotherapy. Interestingly, was niraparib showed to be efficacious not only in BRCA-mutated patients, but also in patients with other alterations of the homologous recombination (HR) system and in patients with unknown alterations. These results position niraparib as the first PARP-inhibitor with clinically and statistically significant results also in patients with no alterations in BRCA 1/2 and other genes involved in the DNA repair system. Even if the results are potentially practice-changing, the action of niraparib must be further studied and deepened
Triple negative breast cancer: new perspectives for targeted therapies
Breast cancer is a heterogeneous disease, encompassing a large number of entities showing different morphological features and having clinical behaviors. It has became apparent that this diversity may be justified by distinct patterns of genetic, epigenetic, and transcriptomic aberrations. The identification of gene-expression microarray-based characteristics has led to the identification of at least five breast cancer subgroups: luminal A, luminal B, normal breast-like, human epidermal growth factor receptor 2, and basal-like. Triple-negative breast cancer is a complex disease diagnosed by immunohistochemistry, and it is characterized by malignant cells not expressing estrogen receptors or progesterone receptors at all, and human epidermal growth factor receptor 2. Along with this knowledge, recent data show that triple-negative breast cancer has specific molecular features that could be possible targets for new biological targeted drugs. The aim of this article is to explore the use of new drugs in this particular setting, which is still associated with poor prognosis and high risk of distant recurrence and death
Tadalafil modulates aromatase activity and androgen receptor expression in a human osteoblastic cell in vitro model
Purpose Phosphodiesterase type-5 inhibitor (PDE5i)
tadalafil administration in men with erectile dysfunction is
associated with increased testosterone/estradiol ratio, leading
to hypothesize a potential increased effect of androgen
action on target tissues. We aimed to characterize, in a cellular
model system in vitro, the potential modulation of
aromatase and sex steroid hormone receptors upon exposure
to tadalafil (TAD).
Methods Human osteoblast-like cells SAOS-2 were chosen
as an in vitro model system since osteoblasts are target
of steroid hormones. Cells were tested for viability upon
TAD exposure, which increased cell proliferation. Then,
cells were treated with/without TAD for several times to
evaluate potential modulation in PDE5, aromatase (ARO),
androgen (AR) and estrogen (ER) receptor expression.
Results Osteoblasts express significant levels of both PDE5
mRNA and protein. Exposure of cells to increasing concentrations
of TAD (10−8–10−7 M) decreased PDE5 mRNA and
protein expression. Also, TAD inhibited ARO mRNA and
protein expression leading to an increase in testosterone levels
in the supernatants. Interestingly, TAD increased total AR mRNA and protein expression and decreased ERα, with an
increased ratio of AR/ER, suggesting preferential androgenic
vs estrogenic pathway activation.
Conclusions Our results demonstrate for the first time
that TAD decreases ARO expression and increases AR
protein expression in human SAOS-2, strongly suggesting
a new control of steroid hormones pathway by PDE5i.
These findings might represent the first evidence of translational
actions of PDE5i on AR, which leads to hypothesize
a growing relevance of this molecule in men with
prostate cancer long-term treated with TAD for sexual
rehabilitation.
Keywords Tadalafil · Osteoblasts · Aromatase · Androgen
receptor · Estrogen recepto
Primary prophylaxis of neutropenia in women affected by breast cancer undergoing adjuvant chemotherapy with fec 100+/- docetaxel. Comparison of efficacy and tolerability between lenograstim and pegfilgrastim
Objectives: evaluate safety and toxicity of a single injection of pegfilgrastim compared
to daily administration of lenograstim in breast cancer patient undergoing adjuvant
chemotherapy
towards the development of interfaces for students with speech disorder and motor impairments
n/
Combined NMDA Inhibitor Use in a Patient With Multisubstance-induced Psychotic Disorder
This document is an Accepted Manuscript reprinted from Journal of Addiction Medicine, Vol. 12 (3): 247-251, May 2018, with permission of Kluwer Law International. Under embargo until 1 May 2019. The Version of Record is available online at DOI: https://doi.org/10.1097/ADM.0000000000000390: Novel psychoactive substance use is a major social concern. Their use may elicit or uncover unpredictably as yet undescribed clinical pictures. We aimed to illustrate a multisubstance use case indistinguishable from paranoid schizophrenia, so to alert clinicians on possibly misdiagnosing substance-induced psychotic disorders. CASE REPORT: We describe a case of a 32-year-old man who started at 18 years with cannabinoids and ketamine, and is currently using N-methyl-D-aspartate (NMDA) antagonists. At age 23, he developed social withdrawal after being assaulted by a stranger, but did not consult psychiatrists until age 26; during this period, he was using internet-purchased methoxetamine and ketamine, and was persecutory, irritable, suspicious, and insomniac and discontinued all received medical prescriptions. He added dextromethorphan to his list of used substances. At age 31, while using phencyclidine, and, for the first time, methoxphenidine, he developed a religious delusion, involving God calling him to reach Him, and the near-death experiences ensured by NMDA antagonists backed his purpose. He received Diagnostic and Statistical Manual of Mental Disorders, 5th Edition diagnosis of multisubstance-induced psychotic disorder and was hospitalized 8 times, 6 of which after visiting the emergency room due to the development of extreme anguish, verbal and physical aggression, and paranoia. He reportedly used methoxphenidine, methoxyphencyclidine, ethylnorketamine, norketamine, and deschlorketamine, to achieve near-death experiences, and eventually to reach God in heavens. CONCLUSIONS: This case points to the need for better control of drugs sold on the internet. It also illustrates that people using NMDA antagonists may present clinical pictures indistinguishable from those of major psychoses and are likely to be misdiagnosed.Peer reviewe
Ammonium recovery from municipal wastewater by ion exchange: Development and application of a procedure for sorbent selection
Ion exchange represents one of the most promising processes for ammonium recovery from municipal wastewater (MWW). However, most previous studies on ammonium ion exchange did not optimize the process or evaluate its robustness under real operational conditions. This experimental study aimed at (i) developing a procedure for the selection of a sorbent for selective ammonium removal/recovery from MWW, (ii) validating the procedure by applying it to several sorbents, (iii) performing a preliminary optimization and robustness assessment of ammonium removal/recovery with the selected sorbent. The application of the procedure to natural and synthetic zeolites and a cation exchange resin confirmed that batch isotherm tests need to be integrated by continuous-flow tests. The selected sorbent, a natural mixture of Chabazite and Phillipsite, resulted in high performances in terms of cation exchange capacity (33 mgN gdry resin-1), ammonium operating capacity (5.2 mgN gdry resin-1), ammonium recovery yield (78-91%) and selectivity towards ammonium. The process performances resulted stable during 7 adsorption/desorption cycles conducted with MWW treatment plant effluents in a 60-cm column. The switch to a highly saline effluent produced in a hotspot of seawater intrusion did not determine significant changes in performances. Contact time was reduced to 6 min without any decrease in performances. Potassium – well tolerated by crops – was selected as the regenerating agent, in the perspective to produce a desorbed product to be re-used as fertilizer. The study shows that Chabazite/Phillipsite has a high capacity to recover ammonium from MWW in a circular economy approach
Geopolymers adsorbents: Production and use
Please click Additional Files below to see the full abstract
Delay prediction system for large-scale railway networks based on big data analytics
State-of-the-art train delay prediction systems do not exploit historical train movements data collected by the railway information systems, but they rely on static rules built by expert of the railway infrastructure based on classical univariate statistic. The purpose of this paper is to build a data-driven train delay prediction system for largescale railway networks which exploits the most recent Big Data technologies and learning algorithms. In particular, we propose a fast learning algorithm for predicting train delays based on the Extreme Learning Machine that fully exploits the recent in-memory large-scale data processing technologies. Our system is able to rapidly extract nontrivial information from the large amount of data available in order to make accurate predictions about different future states of the railway network. Results on real world data coming from the Italian railway network show that our proposal is able to improve the current state-of-the-art train delay prediction systems
- …